Psychedelics and Mental Health: A Population Study

People who are in the emergency department or hospitalized because of hallucinogen use also tend to have chronic health conditions such as asthma, high blood pressure and emergency department visits for depression, compared with the general population. In Monday’s issue of the Canadian Medical Association Journal, Myran and his team start to look at the potential long-term effects of using hallucinogens, specifically risk of death. In the last 10 years, use of drugs such as ketamine, psilocybin, ayahuasca, and MDMA or ecstasy increased in Canada and the United States. In the U.S., the percentage of people reporting they used hallucinogens more than doubled from 3.8 per cent in 2016 to 8.9 per cent in 2021.

Psychiatric symptom indicators

Swainson said there’s a large movement of underground use of hallucinogens, both recreationally and «in pseudo-therapeutic settings,» where an individual guides others on different psychedelic experiences under the premise that it will be therapeutic. Effects of MDMA-assisted Psychotherapy on PTSD Diagnosis and Clinically Meaningful Improvement in CAPS Total Severity Score. The literature flow diagram (Figure 2) summarizes the results of the study selection process (a full list of excluded studies is available in Appendix B in Supplemental Materials). The present report was developed in response to a request from the VA Office of Research and Development (ORD) and VHA Office of Mental Health and Suicide Prevention (OMHSP). The scope was further developed with input from Operational Partners (below) and the ESP Coordinating Center review team.

Data Analysis

The National Institute on Drug Abuse, part of the National Institutes of Health, says the risk of mental health problems caused by ingesting mushrooms in a supervised clinical setting is low, but may be higher outside of a clinical setting. Robert F. Kennedy Jr. said in a social media post last year, before his nomination as U.S. health secretary, that his «mind is open to the idea of psychedelics for treatment.» In a small uncontrolled observational study conducted by the same group as the trial,30 10 adults were administered a 14-week psilocybin-assisted psychotherapy program that included 1–2 psilocybin dosing sessions starting in week 4.

What Is Psychedelic Therapy?

Countries like Canada, the Netherlands, and certain U.S. states have already started allowing limited psychedelic-assisted treatments. With continued advocacy and scientific backing, psychedelics may soon become a mainstream option for treating depression, anxiety, and other mental health conditions. In February, about 40 people organized by the psychedelic advocacy group the Nowak Society gathered in Boulder to talk about are psychedelics addictive the coming changes in Colorado. They included Mandy Grace, who received her state license to administer psychedelic mushrooms, and Amanda Clark, a licensed mental health counselor from Denver, who both praised the therapeutic power of mushrooms. The classical serotonergic psychedelics LSD, psilocybin, mescaline are not known to cause brain damage and are regarded as non-addictive. The exploration of psychedelics in mental health treatment marks an exciting and transformative period in medicine.

Contemporary studies of psychedelic substances have used different treatment protocols for a range of disorders and have employed study designs with differing research aims (eg, safety, feasibility, efficacy, effectiveness, comparative effectiveness). Psychedelic treatments for mental health and substance use disorders are still in an early phase of development and many gaps in the evidence exist, including whether treatment effects vary by patient characteristics or disease severity and whether observed benefits are maintained over time. Other critical gaps in the evidence include whether psychedelic treatment protocols are reproducible and scalable in real-world settings and whether the benefits of discontinuing mental health medications to undergo psychedelic treatments outweigh the risks. In addition to addressing these gaps, areas for future research include study of Veterans with combat-related trauma and study of more diverse populations, particularly with respect to race/ethnicity, socioeconomic status, and rurality.

• To ensure responsiveness to the needs of decision-makers, the program is governed by a Steering Committee composed of health system leadership and researchers.
• At baseline, participants had moderate depression according to the GRID-Hamilton Depression Rating Scale (GRID-HAMD; rated as no depression (0–7), mild depression (8–16), moderate depression (17–23), or severe depression (≥24)).
• Psychedelic plants have been used for celebratory, religious or healing purposes for thousands of years 1–3.
• KFF Health News is a national newsroom that produces in-depth journalism about health issues and is one of the core operating programs at KFF — the independent source for health policy research, polling, and journalism.
• KFF Health News, formerly known as Kaiser Health News (KHN), is a national newsroom that produces in-depth journalism about health issues and is part of KFF, an independent source for health policy research, polling, and journalism.

SETTING CHARACTERISTICS OF INCLUDED PRIMARY STUDIES

Most studies included participants who had alcoholism symptoms been experiencing PTSD symptoms for years and had previously undergone at least 1 medication or psychotherapy trial. Among treatments evaluated for substance use disorders, psilocybin-assisted psychotherapy for alcohol use disorder may reduce alcohol consumption (heavy drinking days and the number of drinks per day), but we have low confidence is this finding (which is based on results of 1 small trial). MDMA-assisted psychotherapy has also been studied for treatment of alcohol use disorder, but results are limited to 1 small observational study and are insufficient to make conclusions. Similarly, evidence on psilocybin as an adjunct to psychotherapy to reduce tobacco use and ayahuasca as treatment for cocaine, cannabis, and other forms of substance use is limited to 1 or a small number of observational studies and is insufficient to make conclusions. Administration of psychedelics for mental health treatment, typically referred to as «psychedelic-assisted therapy,» is a broad term with a very heterogeneous implementation. Despite increasing interest in the clinical application of psychedelic compounds for psychiatric disorders, there is no consensus on how to best integrate the psychedelic experience with evidence-based psychotherapeutic treatment.

Characteristics of Psychedelic Users

• To put the Ontario findings in context, Swainson compared the 7,000 hospital visits reported among hallucinogen users in the study to the almost 400,000 for alcohol and more than 70,000 each for opioids and stimulants such as methamphetamine.
• The most extensively studied intervention involving psychedelics is MDMA-assisted psychotherapy for PTSD.
• The study did not report whether participants had previous experience with treatment for alcohol dependence.
• In this US trial, 95 adults with an average of 14 years of alcohol dependence were randomized to receive 12 psychotherapy sessions with 2 psilocybin dosing sessions or diphenhydramine 50–100mg.
• Some people have reported conversations with people they’ve lost or returning to certain past experiences.

From 2,532 potentially relevant articles, 15 RCTs and 23 observational studies (in 44 publications) met eligibility criteria. Studies enrolled adults with PTSD, depression, obsessive compulsive disorder (OCD), social anxiety, opioid use disorder (OUD), alcohol use disorder, tobacco use, or mixed substance use disorders and mood symptoms. Interventions involved treatment with MDMA, psilocybin, ayahuasca, 5-methoxy-N,N-dimethyltryptamine, and ibogaine with or without psychotherapy or other co-interventions. We used multivariate logistic regression to calculate associations between the past year mental health indicators and use of psychedelics, including lifetime use of any psychedelics, lifetime use of LSD, psilocybin, mescaline/peyote, or peyote, and past year use of LSD.

• However, extended difficulties from using psychedelics can last weeks, months, or years; anxiety and fear, existential struggle, social disconnection, and feeling detached from oneself and one’s surroundings are most common.
• Nonetheless, the small number and size of available studies limits the extent to which firm conclusions can be drawn about the relative contributions of receiving MDMA, undergoing intensive psychotherapy, and other factors (such as participation effects) to observed symptom improvement.
• Still, Woolley said, between the federal ban and new state laws for psychedelics, this is uncharted territory.
• Despite the discovery of vaccines for COVID-19, one of the best security measures to contain the spread of the virus is social distancing and isolation.
• Few serious adverse events were reported across studies, and only 1 event was ultimately attributed to MDMA.
• Countries like Canada, the Netherlands, and certain U.S. states have already started allowing limited psychedelic-assisted treatments.

DATA SOURCES AND SEARCHES

She also added psychedelic medicine (particularly ketamine assisted psychotherapy) and trauma informed medicine to her practice to help her patients further expand into themselves and their lives. Her goal is to help change the medical and mental health care paradigm from numbers-oriented, medication-based sick care to individual-focused well care and liberation to the most realized version of self. In general, recent clinical research studies have not reported long-term harms stemming from psychedelic therapy. Ketamine (the only psychedelic drug currently FDA-approved for mental health treatment) has also not been shown to be addictive when used properly in a controlled medical setting, explains Dr. Radowitz. In recent years, there has been a resurgence of interest in the therapeutic potential of psychedelics, particularly in the treatment of mental health disorders like depression and anxiety. Once dismissed as purely recreational substances, psychedelics such as psilocybin (found in magic mushrooms), LSD, and MDMA are now at the forefront of scientific research, offering hope for those struggling with treatment-resistant conditions.

Researchers are beginning to study whether treatment protocols can be reproduced at scale,11 but this evidence is preliminary. Whether this level of treatment is feasible in everyday practice and whether treatment benefits may still be observed with lower intensity psychotherapy are questions for future research. We identified 7 unique RCTs1–7 of MDMA-assisted psychotherapy compared to psychotherapy with a 0mg placebo or low-dose placebo, and 1 RCT68 that pooled results from 6 of these trials. Studies used the CAPS total severity score (CAPS-4 or CAPS-5, rated 0–136 or 0–80, respectively) to report mean change from baseline in PTSD symptom severity for intervention and comparator groups. CAPS is conducted by a semi-structured interview that accesses an individual’s trauma history as defined by the Diagnostic and Statistical Manual of Mental Disorders. All studies included participants with moderate (total severity score 40–59 on CAPS-472 and 23–34 on CAPS-51) or severe (≥60 on CAPS-4 and ≥35 on CAPS-5) symptoms at baseline (Table 3).